BUZZ-Evercore上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨

路透中文

Mar 04

BUZZ-<a href="https://laohu8.com/S/EVR">Evercore</a>上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨

3月4日 - ** Mirum Pharmaceuticals MIRM.O股价上涨2.15%至89.69美元

** Evercore ISI 将目标价从 101 美元上调至 126 美元，并重申 "跑赢大盘 "评级。

** Evercore分析师克拉克-加特纳（Gavin Clark-Gartner）表示，MIRM "符合所有条件"，其罕见肝病产品组合不断壮大，多项关键试验数据即将公布，竞争前景明朗，利润率真正实现了扩张。

** MIRM 预计将在 2026 年第二季度获得实验性肝病药物 volixibat 的中期数据和 D 型肝炎候选药物 brelovitug 的中期晚期数据

** 券商预计，治疗原发性硬化性胆管炎（一种罕见的慢性进展性肝病）的 volixibat 在全球的未调整峰值销售额为 12 亿美元

** 2025 年 MIRM 股价上涨超过 91%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616554936"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616554936\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616554936?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-04 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616554936","market":"us","top_or_hot":-1,"title":"BUZZ-Evercore上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/EVR\">Evercore</a>上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨</title></head><body><p><span>3月4日</span><span> - </span>** Mirum Pharmaceuticals <span>MIRM.O</span>股价上涨2.15%至89.69美元 </p><p>** Evercore ISI 将目标价从 101 美元上调至 126 美元，并重申 \"跑赢大盘 \"评级。</p><p>** Evercore分析师克拉克-<a href=\"https://laohu8.com/S/IT\">加特纳</a>（Gavin Clark-Gartner）表示，MIRM \"符合所有条件\"，其罕见肝病产品组合不断壮大，多项关键试验数据即将公布，竞争前景明朗，利润率真正实现了扩张。 </p><p>** MIRM 预计将在 2026 年第二季度获得实验性肝病药物 volixibat 的中期数据和 D 型肝炎候选药物 brelovitug 的中期晚期数据</p><p>** 券商预计，治疗原发性硬化性胆管炎（一种罕见的慢性进展性肝病）的 volixibat 在全球的未调整峰值销售额为 12 亿美元 </p><p>** 2025 年 MIRM 股价上涨超过 91% </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Evercore上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Evercore上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-03-04 23:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/EVR\">Evercore</a>上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨</title></head><body><p><span>3月4日</span><span> - </span>** Mirum Pharmaceuticals <span>MIRM.O</span>股价上涨2.15%至89.69美元 </p><p>** Evercore ISI 将目标价从 101 美元上调至 126 美元，并重申 \"跑赢大盘 \"评级。</p><p>** Evercore分析师克拉克-<a href=\"https://laohu8.com/S/IT\">加特纳</a>（Gavin Clark-Gartner）表示，MIRM \"符合所有条件\"，其罕见肝病产品组合不断壮大，多项关键试验数据即将公布，竞争前景明朗，利润率真正实现了扩张。 </p><p>** MIRM 预计将在 2026 年第二季度获得实验性肝病药物 volixibat 的中期数据和 D 型肝炎候选药物 brelovitug 的中期晚期数据</p><p>** 券商预计，治疗原发性硬化性胆管炎（一种罕见的慢性进展性肝病）的 volixibat 在全球的未调整峰值销售额为 12 亿美元 </p><p>** 2025 年 MIRM 股价上涨超过 91% </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL4S3ZS1JH:1","article_id":"2616554936","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616554936","pubTimestamp":1772639801,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Evercore上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨3月4日 - ** Mirum Pharmaceuticals MIRM.O股价上涨2.15%至89.69美元 ** Evercore ISI 将目标价从 101 美元上调至 126 美元，并重申 \"跑赢大盘 \"评级。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","MIRM":"Mirum Pharmaceuticals, Inc."},"translate_title":"Mirum Pharma Rises as BUZZ-Evercore Raises Price Target on Its Liver Disease Drug Potential","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":0.9},"content_text":"BUZZ-Evercore上调Mirum Pharma目标价，看好其肝病药物潜力，Mirum Pharma随之上涨3月4日 - ** Mirum Pharmaceuticals MIRM.O股价上涨2.15%至89.69美元 ** Evercore ISI 将目标价从 101 美元上调至 126 美元，并重申 \"跑赢大盘 \"评级。** Evercore分析师克拉克-加特纳（Gavin Clark-Gartner）表示，MIRM \"符合所有条件\"，其罕见肝病产品组合不断壮大，多项关键试验数据即将公布，竞争前景明朗，利润率真正实现了扩张。 ** MIRM 预计将在 2026 年第二季度获得实验性肝病药物 volixibat 的中期数据和 D 型肝炎候选药物 brelovitug 的中期晚期数据** 券商预计，治疗原发性硬化性胆管炎（一种罕见的慢性进展性肝病）的 volixibat 在全球的未调整峰值销售额为 12 亿美元 ** 2025 年 MIRM 股价上涨超过 91% (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}